Status:
COMPLETED
GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study (JPS 16-03)
Lead Sponsor:
W.L.Gore & Associates
Conditions:
Peripheral Arterial Disease
Eligibility:
All Genders
Brief Summary
This study will confirm device efficacy and safety in the clinical setting after the launch of the GORE® VIABAHN® Endoprosthesis for the treatment of symptomatic peripheral arterial disease in the sup...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Symptomatic peripheral arterial disease in superficial femoral artery lesions
Exclusion
Key Trial Info
Start Date :
August 25 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 14 2022
Estimated Enrollment :
321 Patients enrolled
Trial Details
Trial ID
NCT04706273
Start Date
August 25 2016
End Date
December 14 2022
Last Update
September 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kansai Rousai
Amagasaki, Hyōgo, Japan